Intestinal and tumor microbiome analysis combined with metabolomics of the anti-PD-L1 phase II PERFECT trial for resectable esophageal adenocarcinoma.
Nicolien C. de Clercq(Amsterdam Neuroscience), Max Nieuwdorp(Amsterdam Institute for Addiction Research), Tom van den Ende(Amsterdam Neuroscience), Mark I. van Berge Henegouwen(University of Namur), Sybren L. Meijer(University of Amsterdam), Hanneke W.M. van Laarhoven(Dutch Cancer Society), Suzanne S. Gisbertz(Dutch Cancer Society), Richard van Hillegersberg(University Medical Center Utrecht), Maarten F. Bijlsma(Dutch Cancer Society), Tanja D. de Gruijl(Dutch Cancer Society), Andrei Prodan(AstraZeneca (Netherlands)), Mark Davids(Dana-Farber Cancer Institute), Stella Mook(Utrecht University), Jelle P. Ruurda(University Medical Center Utrecht), Maarten C.C.M. Hulshof(Academic Medical Center), Nicole C.T. van Grieken(Cancer Center Amsterdam), Nadia Haj Mohammad(Utrecht University), Jacques Bergman(University of Amsterdam), Sandor Schokker(Amsterdam University Medical Centers)
Cited by 1
Related Papers
Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
|New England Journal of Medicine|2012|5.5k
Gastric cancer
|The Lancet|2020|4.8k
Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial
|The Lancet Oncology|2015|2.6k
Genome-wide cell-free DNA fragmentation in patients with cancer
|Nature|2019|1.5k
Direct detection of early-stage cancers using circulating tumor DNA
|Science Translational Medicine|2017|1.1k